Although animal models differ from human disease, the magnitude and trans-model consistency of these effects highlight the therapeutic promise of modulating the AKT/c-FOS/IL-6 axis for IL-6-driven chronic inflammatory disorders such as atherosclerosis. This evidence concerns the gene AKT1 and atherosclerosis.